Cerenovus, part of Johnson & Johnson MedTech, has today announced positive primary outcomes from the real-world EXCELLENT registry, focused on stroke-inducing blood clot removal by mechanical thrombectomy, at the Society of Vascular and Interventional Neurology (SVIN) annual meeting (16–19 November 2022, Los Angeles, USA).
Launched by Cerenovus in 2018, the EXCELLENT registry is claimed to be the largest global acute ischaemic stroke registry by the company, collecting patient data, imaging and clots on a per-pass basis, and leveraging independent adjudication by an imaging core lab and clinical events committee.
All patients enrolled in the registry were treated with Cerenovus’ EmboTrap II or EmboTrap III revascularisation devices as a first-line therapy. Offered within the company’s ischaemic portfolio, the EmboTrap family of devices are next-generation stent retrievers designed to remove clots during mechanical thrombectomy procedures—ideally achieving recanalisation at the first pass.
The EXCELLENT registry aims to advance stroke care by characterising the EmboTrap device at multiple hospitals using the technique of choice to reflect current practice patterns, and evaluating the clots retrieved to identify the potential impact different clot compositions can have on patient outcomes. The EXCELLENT data released today comprise 1,000 ischaemic stroke patients from 36 sites worldwide. According to a Cerenovus press release, primary results collected from 2018 to present include:
- Final successful reperfusion of 94.5% achieved with mixed techniques
- Over 50% of patients completed procedures with a single pass of EmboTrap
- First-pass substantial reperfusion of 63% and near-complete reperfusion of 38.1%
- Good-to-ideal clinical outcome in 46.8% of patients
- A very low rate of symptomatic complications of 1.6% and 0.6% in cases with a single pass of EmboTrap
“The positive preliminary findings of this research provide real-world results that demonstrate advances are possible in mechanical thrombectomy procedures to treat ischaemic stroke,” said Mark Dickinson, worldwide president of Cerenovus. “It is encouraging to see these positive results and realise the impact these data can have on improved patient outcomes, and changing the trajectory of stroke.”
The EXCELLENT registry is a large, international, multicentre cohort of ‘all-comers’, featuring a wide range of stroke cases, including patients who have not been considered good thrombectomy candidates in the past. The clots will be analysed by blinded central labs under standard protocol, which furthers prior stroke science research conducted by Cerenovus’ Neuro Thromboembolic Initiative (NTI), the release adds.
To build on its discoveries to date, the EXCELLENT registry is being expanded to 1,000 additional stroke patients and will include new sites in China and Japan; the expanded study will also include the Cerenovus large bore catheter, Embovac, to examine the impact of direct aspiration as a first-line treatment and enable researchers to study clots retrieved through both direction aspiration and stent retrievers.